European Society of Cardiology

ESC Congress | August 27-31, 2011

Note that some of these links take you to a site outside of CardioSource.
CardioSource does not assume responsibility for content of external sites.

SYNTAX Score Value Confirmed, With a Twist

PARIS — Japanese patients with three-vessel disease and moderate to high SYNTAX scores fared better with bypass surgery compared with percutaneous coronary intervention (PCI) -- but so did those with low scores, according to a large registry study.
- Read More
Afib Registry Shows High-Risk Patients Undertreated

PARIS — A first look at a massive international registry of treatment for atrial fibrillation indicates that a high percentage of individuals are not being prescribed anticoagulation treatment that can reduce their risk of stroke, researchers reported here.
- Read More

Intense Exercise Can Take a Toll on the Heart

PARIS — Strenuous exercise, whether performed by elite athletes or competitive weekend warriors, comes with a risk of cardiac disorders, including atrial fibrillation, researchers cautioned.
- Read More
Older Afib Patients Tolerate Anticoagulants

PARIS — A closely monitored cohort of elderly patients with atrial fibrillation who were anticoagulated with vitamin K antagonists appears to have experienced a very low bleeding rate, lending credence to the idea that they can be treated with stroke-preventing therapy, researchers said here.
- Read More

Transient Afib Powerful Predictor of Stroke

PARIS — Transient atrial fibrillation, which typically manifests in the hospital following treatment for acute myocardial infarction but is gone by the time the patient is discharged, might be a harbinger of future stroke, researchers said here.
- Read More
Kids As a Vehicle for Healthy Living

PARIS — Teaching children to adopt a healthier lifestyle may influence their parents to do the same, a study in a single Brazilian private school suggested.
- Read More
TAVI Safe in Lower-Risk Patients

PARIS — Even lower-risk patients with severe aortic stenosis may benefit from transcatheter aortic valve implantation (TAVI), a single-center study showed.
- Read More
Afib Doubles Mortality in Stable Angina Patients

PARIS — Patients with stable angina and documented heart disease whose condition was complicated by the presence of atrial fibrillation had a doubling of the risk of death over a five-year period compared with patients who did not have atrial fibrillation, researchers reported here.
- Read More
New Afib Bad News for Post-MI Nonagenerians

PARIS — For individuals in their 90s who develop atrial fibrillation after an acute myocardial infarction, the outlook for survival is bleak when compared with other elderly MI patients who do not have new-onset arrhythmias, researchers reported here.
- Read More

EXAMINATION

Everolimus-Eluting vs. Bare-Metal Stent for STEMI
PRODIGY

6 vs. 24 Months of Clopidogrel Therapy After Balancing Anti-Intimal Hyperplasia Stent Potency
RUBY-1

Darexaban (YM150) for Secondary Prevention of Ischemic Vascular Events in Patients With ACS
CRISP AMI

Mechanical LV Unloading With Counterpulsation to Reduce Infarct Size Pre-PCI for AMI
Biomarker Related to Mortality Risk

PARIS — An enzyme called cathepsin S appears to be a predictor of mortality, a study of older individuals living in Sweden showed.
- Read More
This Nose Knows Heart Failure

PARIS — A novel computerized sensor that analyzes body order appears to be able to identify the scent of heart failure and to differentiate it from the scent of a healthy person, Swiss researchers said here.
- Read More
Antidote to Factor Xa Inhibitors Shows Promise

PARIS — Oral direct factor Xa inhibitors are an emerging class of drugs that are poised take much of the market from warfarin on a wave of enthusiasm about their ease of use and reported safety, but, amid the hype, one fact remains: drugs like rivaroxaban (Xarelto) and apixaban (Eliquis) don't have an antidote.
- Read More

EVATEL

Remote Follow-Up of Patients With an ICD
RESET

One-Year Clinical and Angiographic Outcomes Comparing Sirolimus-Eluting vs. Everolimus-Eluting Stents
ECOST

Safety of ICD Follow-Up Using Remote Monitoring
STICH

Influence of Mitral Valve Repair on Survival
- Trial Summary
- Discussant Slides
EMPHASIS-HF

Eplerenone Effect on CV Mortality or HF Hospitalization in Subjects with NYHA Class II
Daily Highlights from ESC 2011

EMPHASIS-HF, PACE, CREDO-Kyoto CABG/PCI, SHIFT
- CardioSource Video
Novel HDL-Raising Drug Appears Safe

PARIS — An investigational cholesteryl ester transfer protein (CETP) inhibitor, dalcetrapib, raised HDL cholesterol without any safety concerns in phase IIb dal-VESSEL trial, but it remains to be seen whether that boost in HDL will improve clinical outcomes.
- Read More
ACE Plus ARB Shrinks Heart and Cuts Afib

PARIS — The combination of two classes of angiotensin inhibitors markedly reduces the risk of atrial fibrillation and also reduces the size of enlarged heart chambers, researchers said here.
- Read More
Chocolate Benefits Touted in Study

PARIS — Willy Wonka may have been on to something with that chocolate factory, according to a meta-analysis that suggests chocolate can provide a heart benefit.
- Read More

ARISTOTLE

Apixaban vs. Warfarin for Prevention of Stroke and Systemic Embolism in Atrial Fibrillation
ROCKET-AF

Rivaroxaban vs. Warfarin for Nonvalvular Atrial Fibrillation and Moderate Renal Impairment
- Journal Scan
- Presentation Slides
dal-VESSEL

Vascular Effects and Safety of Dalcetrapib in Patients With or at Risk of CHD
CORP

Colchicine for Recurrent Pericarditis
PURE

Use of Secondary Prevention Drugs for CV Disease in High-Income, Middle-Income, and Low-Income Countries
dal-PLAQUE

Efficacy and Safety of Dalcetrapib on Atherosclerosis Using MRI and PET/CT
- Trial Summary
Anger May Spur AMI While Laughter Confers Benefits

PARIS — New research suggests that patients with cardiovascular disease who have unresolved anger problems may find themselves vulnerable for recurrent heart attacks.
- Read More
Upgrades Help CVD Risk Model Get More Personal

PARIS — HeartScore, a Web-based interactive tool to assess individual 10-year cardiovascular disease risk, has unveiled three new features at the European Society of Cardiology (ESC) meeting.
- Read More

Guideline Issued to Treat CVD in Pregnancy

PARIS — Despite a dearth of prospective, randomized data, the European Society of Cardiology has released guidelines for the management of cardiovascular disease during pregnancy.
- Read More
Hot Line Sizzles Even When Data Are Not So New

PARIS — By the numbers, the European Society of Cardiology meeting is the largest cardiology meeting in the world — more than 30,800 registrants, representing 154 countries, who will have the opportunity to hear and see findings from 4,276 studies.
- Read More

Anticoagulants Top Meeting Agenda

PARIS — The ARISTOTLE trial pitting the novel anticoagulant apixaban against warfarin for preventing stroke in patients with atrial fibrillation looks like it will be the stand-out of this year's meeting of the European Society of Cardiology. This exclusive interview previews the meeting.
- Read More